Results 211 to 220 of about 180,771 (310)

Allogeneic stem cell transplantation with prior pembrolizumab and bendamustine therapy induce complete metabolic response in relapsed/refractory classical hodgkin lymphoma with relapse after nivolumab [PDF]

Ugo Giordano, Agnieszka Kuś, Karolina Kędziora, Mateusz Sawicki, Zbigniew Podgajny, Monika Mordak‐Domagała, Zuzanna Dybko, Jarosław Dybko   +7 more
openalex   +1 more source

Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study [PDF]

, 2014
Uwe Schneider, Marcin Sumila, Judith Robotka, Damien C. Weber, Günther Gruber   +4 more
openalex   +1 more source

A phase I/II study of brentuximab vedotin + AVD in paediatric patients with advanced Hodgkin lymphoma

British Journal of Haematology, EarlyView.
Marco A. Salvino, Flavio A. V. Luisi, Mara A. Pianovski, Franca Fagioli, Sidnei Epelman, Luciana B. A. Lima, Vicente O. Filho, Marco Zecca, Claudio Favre, Ryoji Kobayashi, Yuhki Koga, Rizvan Bush, Yulia Sidi, Xiaofei Zhou, Xiang Bai, Frank Campana, Franco Locatelli   +16 more
wiley   +1 more source

Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.
Patrick Schummer, Caroline Glatzel, Philipp Schrüfer, Ingulf Lawrenz, Gabor Dobos, Ulrike Wehkamp, Svea Hüning, René Stranzenbach, Jan P. Nicolay, Matthias Goebeler, Marion Wobser   +10 more
wiley   +1 more source

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment. [PDF]

Hematol Oncol
Borchmann P, Eichenauer DA, Frigola G, Campo E.   +3 more
europepmc   +1 more source

Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen [PDF]

, 2014
Matthew Mei, Mariëlle J. Wondergem, Joycelynne Palmer, Avichai Shimoni, Justin Hasenkamp, Ni‐Chun Tsai, Jennifer Simpson, Auayporn Nademanee, Andrew Raubitschek, Stephen J. Forman, Amrita Krishnan   +10 more
openalex   +1 more source

First‐line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial

British Journal of Haematology, EarlyView.
Anthony S. Stein, Andrew A. Lane, Kendra L. Sweet, Sumithira Vasu, Alessandra Tosolini, John Katsetos, Marina Konopleva, Naveen Pemmaraju   +7 more
wiley   +1 more source

Risk of hematological malignancies and anticipation in the families of patients with non-Hodgkin and Hodgkin lymphoma. [PDF]

Front Oncol
Akhtar S, Mushtaq AH, Syed H, Elhassan TAM, Alzahrani MJ, Rauf MS, Elshenawy MA, Maghfoor I.   +7 more
europepmc   +1 more source

Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy

, 2013
Brian S. Choi, Gabriela Borsaru, Gianluca Ballinari, Daniel L. Voisin, Nicola Di Renzo   +4 more
openalex   +2 more sources

Role of remdesivir for the treatment of COVID‐19 in patients with hematologic malignancy—A narrative review and expert opinion

European Journal of Clinical Investigation, EarlyView.
Created in BioRender. Ghezzi, S. (2025) https://BioRender.com/q1lticg. Abstract Background COVID‐19 remains a potentially severe condition for immunocompromised individuals, such as patients with hematologic malignancy. These patients are at increased risk of progressing to severe–critical or prolonged COVID‐19.
Malgorzata Mikulska, Matteo Bassetti, Alessandro Busca, Valeria Cento, Maddalena Giannella, Michele Bartoletti   +5 more
wiley   +1 more source